Case Report: High-Level MET Amplification as a Resistance Mechanism of ROS1-Tyrosine Kinase Inhibitors in ROS1-Rearranged Non-Small Cell Lung Cancer

BACKGROUND: Although C-ros oncogene 1 (ROS1) targeted therapies have demonstrated remarkable efficacy in ROS1-rearranged non-small cell lung cancer (NSCLC), patients inevitably develop resistance to ROS1-tyrosine kinase inhibitors (TKIs). Commonly acquired resistance mechanisms include a second muta...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jiangping, Zhou, Ping, Yu, Min, Zhang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155543/
https://www.ncbi.nlm.nih.gov/pubmed/34055614
http://dx.doi.org/10.3389/fonc.2021.645224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155543/
https://www.ncbi.nlm.nih.gov/pubmed/34055614
http://dx.doi.org/10.3389/fonc.2021.645224

Ejemplares similares